Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
November 16, 2022 03:38 PM EST
Pharma

No­var­tis con­sid­ers sell­ing its $5B+ oph­thal­mol­o­gy and res­pi­ra­to­ry units — re­port

Tyler Patchen

News Reporter

As No­var­tis has been fo­cus­ing its core pipeline, and spin­ning off its gener­ics arm San­doz, the com­pa­ny may be look­ing to sell even more. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times